U.S., April 25 -- ClinicalTrials.gov registry received information related to the study (NCT07549646) titled '24VA021; VATCH Trametinib for Ras/MAPK Pathway VAs' on Jan. 20.
Brief Summary: The purpose of this study is to assess the effectiveness and safety of Trametinib (the "Study Drug") in patients with Ras/MAPK pathway driven vascular anomalies (VA). Trametinib has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of metastatic melanoma. Its use in this study is considered experimental because the FDA has not approved the study drug for treating people with VAs.
The study will enroll participants 2 months of age up to 30 years of age that have been diagnosed with Ras/MAPK pathway driven vascular anomalies....